Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
Retrieved on:
Tuesday, November 23, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Marketing, Communications, Other Science, Research, Science, Clinical Trials, Royal commission, Patient, Fibrosis, S1P1, BMY, NYSE, Week, Bristol Myers Squibb, Immunology, Physician, UC, True north, Ulcerative colitis, Adult, European Commission, S1P5, Pharmaceutical industry, True North, Ulcerative Colitis, Zeposia (ozanimod), Bristol Myers Squibb, TRUE NORTH, ULCERATIVE COLITIS, ZEPOSIA (OZANIMOD), BRISTOL MYERS SQUIBB
The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.
Key Points:
- The most common adverse reactions leading to discontinuation were related to liver enzyme elevations (1.1%) in the MS clinical studies.
- Bristol Myers Squibb thanks the patients and investigators involved in the True North clinical trial.
- Bristol Myers Squibb is continuing to evaluate Zeposia in an open-label extension trial, which is ongoing and designed to assess the longer-term profile of Zeposia for the treatment of moderately to severely active UC.
- The company is also investigating Zeposia for the treatment of moderately to severely active Crohns disease in the ongoing Phase 3 YELLOWSTONE clinical trial program.